Expert Interview
Discussing the treatment landscape for hemophilia A with a focus on Biomarin's Roctavian (Valoctocogene Roxaparvovec) & Sanofi's Altuviiio (efanesoctocog alfa)
Ticker(s): BMRN, SNYInstitution: Tulane
- Assistant Professor of Clinical Medicine Section of Hematology & Medical Oncology at Tulane School of Medicine & Associate Director of federally funded hemophilia treatment center
- Site PI and PI on several clinical and pre-clinical trials; clinical focus on hemostasis and clotting and platelet disorders.
- Research has focused on the role of ROTEM, a global visco-elastic study, as a biomarker for multiple hematologic disorders.
What current treatments are there for Hemophilia A? How do these compare to one another?
Added By: max_adminWhere do current treatments fall short? Do Sanofi and Roctavian address these issues?
Added By: max_adminOn a scale of 1 to 10 how would you rate your excitement regarding these new drugs being developed for hemophilia
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
